This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Investors are optimistic as Helix BioPharma Corp. sees a notable uptick in its stock price.
Helix BioPharma Corp. (HBP.TO) is rising today, showing a gain of 1.49% and closing at CA$2.05. This movement reflects a positive sentiment among investors, likely fueled by recent developments in the company’s financial strategies and fundraising efforts.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$106.93M
52W high
$5.40
52W low
$1.10
1W change
-14.11%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 78.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+78.6% Upside
Current Price
C$1.40
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
78.7%
Annualized
90-Day Vol
56.7%
Annualized
Trend (90d)
-6.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.39 | C$1.06 – C$1.82 |
| 60 trading days | C$1.38 | C$0.94 – C$2.03 |
| 90 trading days | C$1.37 | C$0.86 – C$2.19 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With a market cap of CA$142.83 million, Helix BioPharma is making strides in its financial positioning, which could attract further investment interest.
1.49% Gain Today
Helix BioPharma's stock has gained 1.49% today, reflecting investor optimism amid ongoing financial maneuvers.
Bull case
The recent agreement with Kerentech Consulting Ltd. to raise capital could provide Helix BioPharma with the funds it needs to advance its projects. This support might lead to increased revenue and better stock performance.
Bear case
Even with the positive movement, investors should stay cautious. The company hasn’t established a profit margin yet, and future financial results will be crucial for assessing long-term viability.
Recent Financial Developments
Advertisement
Helix BioPharma recently filed interim financial statements for the three and six months ended January 31, 2025. This transparency may boost investor confidence as they evaluate the company's financial health moving forward.
Capital Raising Initiatives
The company has signed a capital raising agreement with Kerentech Consulting Ltd., aiming to close a bridge financing round of USD 13 million. This could provide Helix BioPharma with the resources to support its ongoing projects and strengthen its market position.
Market Response
Investors have responded positively to these developments, as shown by the stock's performance today. However, potential investors should keep in mind the company's lack of profitability and closely monitor upcoming financial results.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
